Faculty Opinions recommendation of Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara.

2011 ◽  
Author(s):  
Yufei Wang ◽  
Karolin Hijazi
Keyword(s):  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Rhesus Macaques ◽  
Infected Female ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Female Rhesus ◽  
Female Rhesus Macaques

scholarly journals The Effects of Chronic Binge Alcohol on the Genital Microenvironment of Simian Immunodeficiency Virus-Infected Female Rhesus Macaques

2014 ◽  
Vol 30 (8) ◽  
pp. 783-791 ◽  
Author(s):  
Nisha Loganantharaj ◽  
Whitney A. Nichols ◽  
Gregory J. Bagby ◽  
Julia Volaufova ◽  
Jason Dufour ◽  
...  
Keyword(s):  
Simian Immunodeficiency Virus ◽  
Rhesus Macaques ◽  
Infected Female ◽  
Immunodeficiency Virus ◽  
Female Rhesus ◽  
Female Rhesus Macaques

scholarly journals Chronic Δ9-Tetrahydrocannabinol Administration May Not Attenuate Simian Immunodeficiency Virus Disease Progression in Female Rhesus Macaques

2014 ◽  
Vol 30 (12) ◽  
pp. 1216-1225 ◽  
Author(s):  
Angela M. Amedee ◽  
Whitney A. Nichols ◽  
Nicole J. LeCapitaine ◽  
Curtis Vande Stouwe ◽  
Leslie L. Birke ◽  
...  
Keyword(s):  
Disease Progression ◽  
Simian Immunodeficiency Virus ◽  
Virus Disease ◽  
Rhesus Macaques ◽  
Immunodeficiency Virus ◽  
Female Rhesus ◽  
Female Rhesus Macaques

scholarly journals Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen

1999 ◽  
Vol 73 (9) ◽  
pp. 7524-7532 ◽  
Author(s):  
Tomas Hanke ◽  
Rachel V. Samuel ◽  
Tom J. Blanchard ◽  
Veronica C. Neumann ◽  
Todd M. Allen ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Rhesus Macaques ◽  
Peripheral Blood Lymphocytes ◽  
Vaccination Regimen ◽  
Boost Regimen ◽  
Boost Vaccination ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus

ABSTRACT DNA and modified vaccinia virus Ankara (MVA) are vaccine vehicles suitable and safe for use in humans. Here, by using a multicytotoxic T-lymphocyte (CTL) epitope gene and a DNA prime-MVA boost vaccination regimen, high levels of CTLs specific for a single simian immunodeficiency virus (SIV) gag-derived epitope were elicited in rhesus macaques. These vaccine-induced CTLs were capable of killing SIV-infected cells in vitro. Fluorescence-activated cell sorter analysis using soluble tetrameric major histocompatibility complex-peptide complexes showed that the vaccinated animals had 1 to 5% circulating CD8+ lymphocytes specific for the vaccine epitope, frequencies comparable to those in SIV-infected monkeys. Upon intrarectal challenge with pathogenic SIVmac251, no evidence for protection was observed in at least two of the three vaccinated animals. This study does not attempt to define correlates of protective immunity nor design a protective vaccine against immunodeficiency viruses, but it demonstrates clearly that the DNA prime-MVA boost regimen is an effective protocol for induction of CTLs in macaques. It also shows that powerful tools for studying the role of CTLs in the control of SIV and human immunodeficiency virus infections are now available: epitope-based vaccines, a protocol for an effective induction of CTLs in primates, and a simple and sensitive method for quantitation of epitope-specific T cells. The advantages of the DNA prime-MVA boost regimen as well as the correlations of tetramer staining of peripheral blood lymphocytes with CTL killing in vitro and postchallenge control of viremia are discussed.

scholarly journals CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection

2015 ◽  
Vol 89 (8) ◽  
pp. 4690-4695 ◽  
Author(s):  
Suefen Kwa ◽  
Shanmugalakshmi Sadagopal ◽  
Xiaoying Shen ◽  
Jung Joo Hong ◽  
Sailaja Gangadhara ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Cd8 T Cells ◽  
Igg Antibodies ◽  
Strong Response ◽  
Viral Control ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Siv Infection

Here, we show that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS. Analyses of serum IgG antibodies to linear peptides of SIV Env revealed a strong response to V2, with targeting of fewer epitopes in the immunodominant region of gp41 (gp41-ID) and the V1 region as a correlate for enhanced protection. Greater expansion of antiviral CD8 T cells in the gut correlated with long-term viral control.

scholarly journals Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity

2001 ◽  
Vol 82 (9) ◽  
pp. 2215-2223 ◽  
Author(s):  
Sally Sharpe ◽  
Natasha Polyanskaya ◽  
Mike Dennis ◽  
Gerd Sutter ◽  
Tomáš Hanke ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Vaccine Development ◽  
Cytotoxic T Lymphocyte ◽  
Rhesus Macaques ◽  
Lymphoid Tissues ◽  
Specific Response ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus ◽  
Definition Of

A major aim in AIDS vaccine development is the definition of strategies to stimulate strong and durable cytotoxic T lymphocyte (CTL) responses. Here we report that simian immunodeficiency virus (SIV)-specific CTL developed in 4/4 macaques following a single intramuscular injection of modified vaccinia virus Ankara (MVA) constructs expressing both structural and regulatory/accessory genes of SIV. In two animals Nef-specific responses persisted, but other responses diminished and new responses were not revealed, following further vaccination. Vaccination of another two macaques, expressing Mamu A*01 MHC class I, with MVA constructs containing nef and gag–pol under the control of the moderate strength natural vaccinia virus early/late promoter P7.5, again induced an early Nef-specific response, whereas responses to Gag remained undetectable. Anti-vector immunity induced by this immunization was shown to prevent the efficient stimulation of CTL directed to the cognate Gag epitope, p11C C-M, following vaccination with another MVA construct expressing SIV Gag–Pol under a strong synthetic vaccinia virus-specific promoter. In contrast, vaccination of a previously unexposed animal resulted in a SIV-specific CTL response widely disseminated in lymphoid tissues including lymph nodes associated with the rectal and genital routes of SIV entry. Thus, despite the highly attenuated nature of MVA, repeated immunization may elicit sufficient anti-vector immunity to limit the effectiveness of later vaccination.

scholarly journals Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239

2002 ◽  
Vol 76 (14) ◽  
pp. 7187-7202 ◽  
Author(s):  
Helen Horton ◽  
Thorsten U. Vogel ◽  
Donald K. Carter ◽  
Kathy Vielhuber ◽  
Deborah H. Fuller ◽  
...  
Keyword(s):  
Vaccinia Virus ◽  
Simian Immunodeficiency Virus ◽  
Neutralizing Antibodies ◽  
Viral Vector ◽  
Rhesus Macaques ◽  
Neutralizing Antibody ◽  
Challenge Virus ◽  
Boost Regimen ◽  
Modified Vaccinia Virus Ankara ◽  
Immunodeficiency Virus

ABSTRACT Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be a challenge. Most biological isolates of HIV are difficult to neutralize, so that conventional subunit-based antibody-inducing vaccines are unlikely to be very effective. In the rhesus macaque model, some protection was afforded by DNA/recombinant viral vector vaccines. However, these studies used as the challenge virus SHIV-89.6P, which is neutralizable, making it difficult to determine whether the observed protection was due to cellular immunity, humoral immunity, or a combination of both. In this study, we used a DNA prime/modified vaccinia virus Ankara boost regimen to immunize rhesus macaques against nearly all simian immunodeficiency virus (SIV) proteins. These animals were challenged intrarectally with pathogenic molecularly cloned SIVmac239, which is resistant to neutralization. The immunization regimen resulted in the induction of virus-specific CD8+ and CD4+ responses in all vaccinees. Although anamnestic neutralizing antibody responses against laboratory-adapted SIVmac251 developed after the challenge, no neutralizing antibodies against SIVmac239 were detectable. Vaccinated animals had significantly reduced peak viremia compared with controls (P < 0.01). However, despite the induction of virus-specific cellular immune responses and reduced peak viral loads, most animals still suffered from gradual CD4 depletion and progressed to disease.

Sign in / Sign up

Export Citation Format

Share Document